食管疾病2026，Vol.8Issue(1)：22-27,38,7.DOI:10.15926/j.cnki.issn2096-7381.2026.01.004
Stathmin联合免疫指标对食管癌同步放化疗患者疗效及预后的预测价值
Predictive Value of Stathmin Combined with Immune Indicators for Efficacy and Prognosis of Synchronous Chemoradiotherapy in Patients with Esophageal Cancer
于明军1
作者信息
- 1. 濮阳油田总医院,河南 濮阳,457001
- 折叠
摘要
Abstract
Objective To evaluate the predictive efficacy of Stathmin and T-lymphocyte subsets for therapeutic outcomes and prognosis in esophageal cancer patients undergoing concurrent chemoradiotherapy.Methods 110 patients with locally advanced esophageal cancer receiving concurrent chemoradiotherapy at Puyang oilfield general hospital from January 2022 to December 2023 were enrolled and divide into an ineffective group of 23 cases and an effective group of 87 cases according to the efficacy.Serum Stathmin levels and T-lymphocyte subsetswere measured before and after treatment.After a 12-month follow-up,patients were stratified into a poor prognosis group(n=29)and a good prognosis group(n=81).Associations between these markers and prognosis were analyzed.Receiver operating characteristic(ROC)curves were used to analyze the predictive power of different indicators on prognosis.Results The incidence of poor prognosis in the effective group(17.24%,15/87)was significantly lower than that in the ineffective group(60.87%,14/23)(χ2=17.840,P＜0.001).Post-treatment serum Stathmin level in the effective group was significantly lower than that in the ineffective group(P＜0.001),with more pronounced increases in CD4+and decreases in CD8+(P＜0.001).Compared to the poor prognosis group,the good prognosis group showed significantly lower Stathmin levels and CD4+/CD8+ratios(P＜0.001),but higher CD4+and CD8+proportions(P＜0.001).Multivariate logistic regression identified elevated Stathmin(OR=2.983,P＜0.001)and CD4+/CD8+ratio(OR=1.338,P＜0.001)as independent risk factors,while increased CD4+and CD8+were protective factors.ROC analysis revealed higher predictive efficacy for the combination of Stathmin and CD4+/CD8+than either marker alone.Patients with serum Stathmin＞4.50 μg·L-1 or CD4+/CD8+＞1.18 had increased risk of poor prognosis.Survival analysis showed that patients with high Stathmin expression or a high CD4+/CD8+ratio had significantly shorter progression-free survival(P＜0.001,P=0.017,respectively).Conclusion Combined assessment of serum Stathmin and CD4+/CD8+ratio provides high predictive efficacy for prognosis in esophageal cancer patients treated with concurrent chemoradiotherapy with high levels associatedwith inferior PFS.关键词
食管癌/同步放化疗/疗效/预后/stathmin/CD4+/CD8+Key words
esophageal cancer/concurrent chemoradiotherapy/curative effect/prognosis/Stathmin/CD4+/CD8+分类
医药卫生引用本文复制引用
于明军..Stathmin联合免疫指标对食管癌同步放化疗患者疗效及预后的预测价值[J].食管疾病,2026,8(1):22-27,38,7.
